Publications

• June 15, 2015
  

  Nonclinical Models for Antituberculosis Drug Development: A Landscape Analysis

  Gumbo T, Lenaerts AJ, Hanna D, Romero K, Nuermberger E. Nonclinical Models for Antituberculosis Drug Development: A Landscape Analysis. The Journal of Infectious Diseases. 2015 Jun 15;211 Suppl 3:S83–95.

• June 12, 2015
  

  Development of a Patient-Reported Outcome Instrument to Assess Complex Activities of Daily Living and Interpersonal Functioning in Persons with Mild Cognitive Impairment: The Qualitative Research Phase

• June 1, 2015
  

  Patient-Reported Outcomes In Cancer Drug Development And US Regulatory Review: Perspectives From Industry, The Food And Drug Administration, And The Patient

• April 23, 2015
  

  The TREAT-NMD Advisory Committee for Therapeutics (TACT): An Innovative de-Risking Model to Foster Orphan Drug Development

• April 1, 2015
  

  Defining the Needs for next Generation Assays for Tuberculosis

  Denkinger CM, Kik SV, Cirillo DM, Casenghi M, Shinnick T, Weyer K, Gilpin C, Boehme CC, Schito M, Kimerling M, Pai M. Defining the Needs for next Generation Assays for Tuberculosis. The Journal of Infectious Diseases. 2015 Apr 1;211 Suppl 2:S29–38.